Junshi Biosciences and Eli Lilly have entered into an agreement to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19.
At the beginning of the outbreak, Junshi Biosciences, a Chinese biopharma specialising in the discovery, development and commercialisation of novel therapies, launched one of the industry’s first R&D efforts aimed at discovering therapies to combat COVID-19.
Multiple neutralising antibodies have been engineered, with the lead asset poised to enter clinical testing in the second quarter.
“Since the outbreak of COVID-19, we have been working diligently to join the fight against the pandemic. Entering into this agreement with Lilly empowers us to accelerate the clinical development of Junshi SARS-CoV-2 antibodies globally,” said Ning Li, Junshi Biosciences’ CEO.
“At the same time, by leveraging Lilly’s global presence and capabilities, we have the potential to reach broader COVID-19 patient populations in a wider range of countries and regions.”
Daniel Skovronsky, MLilly’s Chief Scientific Officer and president of Lilly Research Laboratories, said: “The data generated by Junshi Biosciences suggest the lead antibody may have appropriate properties to support testing its therapeutic use in patients as well as exploring its potential for preventing infection in at-risk individuals.
“We look forward to partnering with Junshi Biosciences to quickly begin testing this potential new therapy in clinical trials.”
Lilly will receive an exclusive license to conduct clinical development, manufacturing and distribution of products outside of Greater China. Junshi Biosciences will maintain all rights in Greater China.